Loading people...
Anne Osdoit is a Partner at Soffinova Partners, a leading European venture capital firm. She is an influential investor specializing in the life sciences sector, focusing on biotech and medtech innovations.
Anne Osdoit primarily invests in life sciences companies, including those developing novel therapeutics, diagnostics, medical devices, and digital health solutions. Her focus areas often include oncology, rare diseases, and other critical medical fields.
Anne Osdoit works at Soffinova Partners, a prominent European venture capital firm with offices in Paris, London, and other key locations.
Anne Osdoit is a Partner at Sofinnova Partners and the CEO of Moon Surgical, currently based in Paris, France. She leads the firm's MD Start medical device accelerator, where she actively builds early-stage companies and recently guided Moon Surgical to an $85 million Series B funding round backed by NVIDIA. Previously, she served as the founding CEO for multiple incubated startups, including Gradient Denervation Technologies, which secured a €14 million Series A financing in 2023, as well as SafeHeal and May Health. Her extensive board experience includes director roles at eCential Robotics and Cardiologs Technologies, the latter of which was acquired by Philips in 2021. Trained as a biomedical engineer at École Polytechnique and Johns Hopkins University, Osdoit focuses her investments and operational leadership on translating clinical needs into commercial medical device and robotic surgery innovations.
Anne Osdoit is a distinguished Partner at Soffinova Partners, a prominent European venture capital firm renowned for its deep expertise in life sciences. In her pivotal role, Anne is instrumental in shaping the future of healthcare by identifying, investing in, and nurturing innovative companies across the biotech and medtech landscapes. Her strategic vision and profound industry knowledge make her a key figure in the venture capital ecosystem.
At Soffinova Partners, Anne Osdoit's investment focus is sharply defined within the life sciences sector. She actively seeks out pioneering startups and growth-stage companies developing novel therapeutics, diagnostics, medical devices, and digital health solutions. Her portfolio interests span critical areas such as oncology, rare diseases, neuroscience, and cardiovascular health, always with an eye towards technologies that promise significant patient impact and market disruption. Anne is committed to backing scientific breakthroughs that address unmet medical needs and improve human health globally.
Anne Osdoit brings a rich and diverse background to her role as a venture capitalist. Prior to joining Soffinova Partners, she accumulated extensive experience within the pharmaceutical and biotechnology industries. Her career journey has equipped her with a comprehensive understanding of drug discovery, clinical development, regulatory pathways, and commercialization strategies. This hands-on operational expertise, combined with a strong scientific foundation, provides her with a unique perspective when evaluating potential investments. She leverages this deep industry insight to conduct thorough due diligence and provide invaluable strategic guidance to the management teams of Soffinova's portfolio companies.
While specific investment details are often proprietary, Anne Osdoit has been instrumental in supporting numerous companies that are now at the forefront of medical innovation. Her contributions help these ventures navigate complex development cycles, secure further funding, and ultimately bring life-changing products to market. She is known for her collaborative approach, working closely with founders and executives to build robust businesses that deliver both scientific progress and strong financial returns. Her work at Soffinova Partners underscores the firm's commitment to fostering a healthier future through strategic capital deployment and expert mentorship.
Anne Osdoit's leadership at Soffinova Partners exemplifies the firm's dedication to advancing life sciences. Her expertise, strategic acumen, and passion for innovation continue to drive significant progress in the biotech and medtech sectors, making her a respected and influential investor in European venture capital.
